IL10 and breast carcinoma: One trial evaluated PEGylated human IL-10 (AM0010) in solid tumors (n = 51) and showed an acceptable toxicity profile with evidence of systemic immune activation and antitumor activity (27% overall response rate).52 To the best of our knowledge, there are no plans for further evaluation of PEGylated human IL-10 in breast cancer patients.